Jemperli
Payments companies reported to CMS as associated with Jemperli. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Jemperli, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Jemperli
These are the largest totals companies reported as associated with Jemperli. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joshua Kesterson | Newport, PA | Gynecologic Oncology | $240,040.47 |
| John Chan | San Francisco, CA | Gynecologic Oncology | $232,976.58 |
| Dana Chase | Los Angeles, CA | Gynecologic Oncology | $191,871.98 |
| Mark Shahin | Hershey, PA | Gynecologic Oncology | $178,468.82 |
| Amina Ahmed | Chicago, IL | Gynecologic Oncology | $169,510.71 |
| Dario Roque | Chicago, IL | Gynecologic Oncology | $156,976.47 |
| Thomas Krivak | Pittsburgh, PA | Gynecologic Oncology | $144,728.67 |
| Sharyn Lewin | Teaneck, NJ | Gynecologic Oncology | $140,337.24 |
| Chirag Shah | Seattle, WA | Gynecologic Oncology | $114,126.42 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $111,486.15 |
Prescribed Jemperli?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.